James A. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
James A. Lee has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer H. Kuo
Columbia University Irving Medical Center, Department of Endocrine Surgery, 177 Fort Washington Ave, New York, NY, 10032, United States
11 shared publications - Catherine McManus
Department of Surgery, Division of Endocrine Surgery, Columbia University Medical Center, New York, NY, USA
7 shared publications - Eric J. Kuo
Department of Surgery, Division of Endocrine Surgery, Columbia University Medical Center, New York, NY, USA
5 shared publications - Elliot Jonathan Mitmaker
Department of Surgery, McGill University, Montreal, Quebec, Canada
2 shared publications - Rachel Liou
Section of Endocrine Surgery, Columbia University, New York, NY
2 shared publications - Yinin Hu
Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
2 shared publications
Latest Publications
- 13 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 256, 116920
Radiofrequency ablation for nodal recurrence in papillary thyroid carcinoma
- 13 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 256, 116920
Radiofrequency ablation for nodal recurrence in papillary thyroid carcinoma
- 1 January 2025
- Published by Springer Nature
- p. 279-287
Observation Versus Surgery for Pregnant Patients with Primary Hyperparathyroidism
- 1 January 2025
- Published by Springer Nature
- p. 279-287
Observation Versus Surgery for Pregnant Patients with Primary Hyperparathyroidism
- 25 September 2024
- Published by Springer Nature
- p. 69-77
Laparoscopic Adrenalectomy: Transperitoneal Approach
- 25 September 2024
- Published by Springer Nature
- p. 69-77
Laparoscopic Adrenalectomy: Transperitoneal Approach
- 5 September 2024
- Published by Springer Nature
- p. 223-227
Fostering Productive Mentor-Mentee Relationships
- 5 September 2024
- Published by Springer Nature
- p. 223-227
Fostering Productive Mentor-Mentee Relationships
- Open Access
EndoGPT: A Proof-of-concept Large Language Model Based Assistant for the Management of Thyroid Nodules
Large language models (LLMs) are increasingly being explored for their potential to simulate clinical reasoning. Here, we demonstrate our initial experience using the GPT-4o LLM along with prompt engineering and knowledge retrieval to develop EndoGPT, a clinical decision support tool for the management of thyroid nodules. In a pilot study of 50 cases, EndoGPT demonstrated an 83% concordance rate with expert surgeons’ assessments and plans. The highest concordance was in diagnosis (93%), followed by the need for an operation (82%) and type of operation (69%). This work suggests that LLM-based assistants may play a useful role in assisting clinicians in the future.
Open AccessEndoGPT: A Proof-of-concept Large Language Model Based Assistant for the Management of Thyroid Nodules
Large language models (LLMs) are increasingly being explored for their potential to simulate clinical reasoning. Here, we demonstrate our initial experience using the GPT-4o LLM along with prompt engineering and knowledge retrieval to develop EndoGPT, a clinical decision support tool for the management of thyroid nodules. In a pilot study of 50 cases, EndoGPT demonstrated an 83% concordance rate with expert surgeons’ assessments and plans. The highest concordance was in diagnosis (93%), followed by the need for an operation (82%) and type of operation (69%). This work suggests that LLM-based assistants may play a useful role in assisting clinicians in the future.
- 4 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 460-466
Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution
Background: Molecular testing (MT) has become standard practice to more accurately rule out malignancy in indeterminate Bethesda III (BIII) thyroid lesions. We sought to assess the adoption of this technology and its impact on cytology reporting, malignancy yield, and rates of surgery across community and academic sites affiliated with a tertiary medical center. Methods: We performed a retrospective cross-sectional study including all fine-needle aspirations (FNAs) analyzed at our institution from 2017 to 2021. We analyzed trends in MT utilization by platform and by community or academic site. We compared BIII call rates, MT utilization rates, rates of subsequent surgery, and malignancy yield on final pathology before and after MT became readily available using chi-square analysis and linear regression. Results: A total of 8960 FNAs were analyzed at our institution from 2017 to 2021. There was broad adoption of MT across both community and academic sites. There was a significant increase in both the BIII rate and the utilization of MT between the pre- and post-MT periods ( p < 0.001 and p < 0.001). There was no significant change in the the malignancy yield on final pathology (57.1% vs. 50.0%, p = 0.347), while the positive predictive value of MT decreased from 85% to 50% ( p = 0.008 [confidence interval 9.5–52.5% decrease]). Conclusions: The use of MT increased across the institution over the study period, with the largest increase seen after a dedicated pass for MT was routinely collected. This increased availability of MT may have led to an unintended increase in the rates of BIII lesions, MT utilization, and surgery for benign nodules. Physicians who use MT should be aware of potential consequences of its adoption to appropriately counsel patients.
- 4 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 460-466
Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution
Background: Molecular testing (MT) has become standard practice to more accurately rule out malignancy in indeterminate Bethesda III (BIII) thyroid lesions. We sought to assess the adoption of this technology and its impact on cytology reporting, malignancy yield, and rates of surgery across community and academic sites affiliated with a tertiary medical center. Methods: We performed a retrospective cross-sectional study including all fine-needle aspirations (FNAs) analyzed at our institution from 2017 to 2021. We analyzed trends in MT utilization by platform and by community or academic site. We compared BIII call rates, MT utilization rates, rates of subsequent surgery, and malignancy yield on final pathology before and after MT became readily available using chi-square analysis and linear regression. Results: A total of 8960 FNAs were analyzed at our institution from 2017 to 2021. There was broad adoption of MT across both community and academic sites. There was a significant increase in both the BIII rate and the utilization of MT between the pre- and post-MT periods ( p < 0.001 and p < 0.001). There was no significant change in the the malignancy yield on final pathology (57.1% vs. 50.0%, p = 0.347), while the positive predictive value of MT decreased from 85% to 50% ( p = 0.008 [confidence interval 9.5–52.5% decrease]). Conclusions: The use of MT increased across the institution over the study period, with the largest increase seen after a dedicated pass for MT was routinely collected. This increased availability of MT may have led to an unintended increase in the rates of BIII lesions, MT utilization, and surgery for benign nodules. Physicians who use MT should be aware of potential consequences of its adoption to appropriately counsel patients.
- 22 January 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (3) , 388-398
Does the Adoption of Molecular Testing Cause Decreased Thyroidectomy Rates in a National Cohort? A Quasiexperimental Study of High- Versus Low-Adoption States
Background: Over the last decade, the utilization of molecular testing (MT) for the evaluation of thyroid nodules has increased. Rates and patterns of adoption of MT and its effect on thyroidectomy rates nationally are unknown. Varying rates of MT adoption at the state level provide an opportunity to study the effects of MT on thyroidectomy rates using a quasiexperimental study design. Methods: We performed a retrospective analysis of American adult patients in the Merative™ MarketScan ® Research Databases who underwent thyroid fine-needle aspiration (FNA) from 2011 to 2021. MT included commercially available DNA and RNA platforms and traditional targeted mutational analysis. Interrupted time series analysis was used to evaluate the inflection of MT adoption and thyroidectomy rates after 2015. Difference-in-differences (DID) analysis was used to causally analyze the effect of MT adoption on thyroidectomy rates in high-adoption (at least a 10% increase in MT utilization) versus low-adoption states (no more than 5% increase in MT utilization) from 2015 to 2021. Results: We identified 471,364 patients who underwent thyroid FNA. The utilization of MT increased over the study period from 0.01% [confidence interval, CI: 0.00% to 0.02%] to 10.1% [CI: 9.7% to 10.5%], in 2021, with an immediate (β2 = 1.61, p = 0.002) and deeper (β3 = 0.6, p < 0.001) increase in MT adoption after 2015. Utilization of MT was lower in black patients, the elderly, rural areas, and patients with Medicaid ( p < 0.05). Thyroidectomy rates were inversely correlated with MT utilization ( r = −0.98, p < 0.0001). From 2015 to 2021, the average MT utilization rate increased from 2.4% to 15.3% in high-adoption states and 1.6% to 5.6% in low-adoption states. In low-adoption states, thyroidectomy rates decreased more but to similar levels (18.5–13.2%) compared with high-adoption states (15.9–13.4%) with an adjusted DID rate of −3.3% [CI −5.6% to −0.8%]. Conclusions: The acceleration in adoption of MT after 2015 likely coincides with the publication of American Thyroid Association guidelines. Black, elderly, and rural patients are less likely to receive MT. Although thyroidectomy rates were inversely correlated with MT utilization, our study suggests that this correlation is not causal. The effect of MT on thyroidectomy rates may be overshadowed by decreasing aggressiveness of thyroid nodule evaluation.
- 22 January 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (3) , 388-398
Does the Adoption of Molecular Testing Cause Decreased Thyroidectomy Rates in a National Cohort? A Quasiexperimental Study of High- Versus Low-Adoption States
Background: Over the last decade, the utilization of molecular testing (MT) for the evaluation of thyroid nodules has increased. Rates and patterns of adoption of MT and its effect on thyroidectomy rates nationally are unknown. Varying rates of MT adoption at the state level provide an opportunity to study the effects of MT on thyroidectomy rates using a quasiexperimental study design. Methods: We performed a retrospective analysis of American adult patients in the Merative™ MarketScan ® Research Databases who underwent thyroid fine-needle aspiration (FNA) from 2011 to 2021. MT included commercially available DNA and RNA platforms and traditional targeted mutational analysis. Interrupted time series analysis was used to evaluate the inflection of MT adoption and thyroidectomy rates after 2015. Difference-in-differences (DID) analysis was used to causally analyze the effect of MT adoption on thyroidectomy rates in high-adoption (at least a 10% increase in MT utilization) versus low-adoption states (no more than 5% increase in MT utilization) from 2015 to 2021. Results: We identified 471,364 patients who underwent thyroid FNA. The utilization of MT increased over the study period from 0.01% [confidence interval, CI: 0.00% to 0.02%] to 10.1% [CI: 9.7% to 10.5%], in 2021, with an immediate (β2 = 1.61, p = 0.002) and deeper (β3 = 0.6, p < 0.001) increase in MT adoption after 2015. Utilization of MT was lower in black patients, the elderly, rural areas, and patients with Medicaid ( p < 0.05). Thyroidectomy rates were inversely correlated with MT utilization ( r = −0.98, p < 0.0001). From 2015 to 2021, the average MT utilization rate increased from 2.4% to 15.3% in high-adoption states and 1.6% to 5.6% in low-adoption states. In low-adoption states, thyroidectomy rates decreased more but to similar levels (18.5–13.2%) compared with high-adoption states (15.9–13.4%) with an adjusted DID rate of −3.3% [CI −5.6% to −0.8%]. Conclusions: The acceleration in adoption of MT after 2015 likely coincides with the publication of American Thyroid Association guidelines. Black, elderly, and rural patients are less likely to receive MT. Although thyroidectomy rates were inversely correlated with MT utilization, our study suggests that this correlation is not causal. The effect of MT on thyroidectomy rates may be overshadowed by decreasing aggressiveness of thyroid nodule evaluation.
- 31 December 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 188
Introduction to papers presented at the festschrift of Janice L. Pasieka
- 31 December 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 188
Introduction to papers presented at the festschrift of Janice L. Pasieka